Series B Funding
The funds will be used to strengthen the development of its proprietary AI and enhance technology-enabled delivery of clinical trials.
Funding will help take its DTx solutions through regulatory approvals and to market in the UK and US.
The investment will support further growth in key markets.
The funding is the largest raise in men's health in Europe to date.
New partners include companies across life sciences, insurance, health systems and global development.
The investment will support the development of Ada's symptom assessment and care navigation platform.
The funds will be used to develop the firm’s non-invasive blood sensing technology.
The funds will be used to drive European leadership in digital chronic disease prevention and management.